Entospletinib Dimesylate/Idelalisib

N/A

Report date: 2023/05/05 17:36:44

Base Information

Drug NameEntospletinib Dimesylate/Idelalisib
Drug Alias Nameentospletinib/idelalisibIdelalisib/Entospletinib Dimesylate
ClassificationSmall molecules
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitorsSpleen tyrosine kinase inhibitors
TargetsSpleen tyrosine kinasePhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, Mantle-CellLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes IdelalisibEntospletinib Dimesylate
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsHematologic NeoplasmsLymphoma, Mantle-CellLymphoma, Large B-Cell, Diffuse +[5] 

Other Information

ATC CodeN/A
Related LinksN/A